Hypertension (HTN) is a common disease state associated with extensive morbidity and mortality worldwide. It is often difficult for patients with HTN to achieve and maintain a goal blood pressure (BP), despite there being many effective treatment options available. Sacubitril/valsartan is a first-inclass angiotensin receptor neprilysin inhibitor (ARNI) that has garnered approval by the US Food and Drug Administration and the European Medicines Agency as a first-line treatment for heart failure with reduced ejection fraction. During clinical trials for heart failure as well as in independent trials for HTN, sacubitril/valsartan has demonstrated safety and efficacy when it comes to BP lowering, making it a promising antihypertensive agent. Most trials of sacubitril/valsartan were 8 to 12 weeks in length and demonstrated a clinically relevant BP lowering that was frequently more significant than its comparators. While more data are needed to confirm its role as an antihypertensive agent, the data available are promising and it is anticipated that sacubitril/valsartan will gain an indication of HTN.
Introduction
The global prevalence of elevated blood pressure (BP; defined as systolic BP [SBP] and/or diastolic BP [DBP] ≥140/90 mmHg) in adults is estimated to be approximately 22% and was the leading cause of death worldwide in 2010. 1, 2 Once diagnosed, treatment of hypertension (HTN) to achieve goal BP is key to reduce morbidity and mortality related to cardiovascular disease (CVD). The 2017 ACC/AHA/AAPA/ABC/ ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults recommends thiazide diuretics, angiotensin converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and calcium channel blockers (CCB) as primary agents used to treat HTN. 3 While patients with HTN may be started on a single antihypertensive, many will require two antihypertensives at baseline due to the presence of stage 2 HTN and/or will ultimately require ≥ two antihypertensives to reach their BP goal. 3 When more than one agent is required, the antihypertensive agents used should have complementary mechanisms of action. 3 Sacubitril/valsartan is a novel combination drug containing an existing ARB (valsartan) and a neprilsyn inhibitor (sacubitril) approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of patients with heart failure with reduced ejection fraction (HFrEF). 4, 5 While not yet approved for the treatment of HTN, sacubitril/valsartan has been evaluated for this indication in multiple clinical trials and has demonstrated both safety and efficacy in this condition. The beneficial effects of sacubitril/valsartan in HTN are related to inhibition of the catabolism of natriuretic peptides by neprilysin and blockade of angiotensin II, resulting in systemic vasodilation, natriuresis, and diuresis. 6 This review aims to present and discuss the current evidence regarding the use of sacubitril/valsartan for the treatment of HTN. We conducted an English language MEDLINE search through May 2018 using the search terms 'sacubitril/valsartan', 'LCZ696', and 'hypertension'. A manual search for references identified in these trials and review articles was performed to identify additional relevant articles. ISSN (Table 1) . Interestingly, the largest proportion of patients who experienced at least one adverse effect occurred in the placebo group with diarrhea being the most common, followed by headache, dizziness, and cough. 15 A small study by Wang and colleagues compared sacubitril/ valsartan 400 mg orally once daily with valsartan 320 mg orally once daily over 4 weeks in 75 patients with salt-sensitive HTN. At 4 weeks, patients receiving sacubitril/valsartan experienced increased natriuresis, diuresis, and decreased BP, compared to patients receiving valsartan. The change in SBP was -13.3 mmHg for those in the sacubitril/valsartan group, compared with -5.8 mmHg for those in the valsartan group (p=0.002). The proportions of patients experiencing adverse events were similar between groups (32.4 versus 32.8%; p-value not reported), and the most commonly reported adverse events were dizziness, hematuria, headache, nasopharyngitis, and cough. 16 Another recent study compared sacubitril/valsartan 200 mg orally once daily with add-on amlodipine 5 mg orally once daily therapy with amlodipine 5 mg orally once daily monotherapy in 251 patients with HTN over 12 weeks. Not surprisingly, sacubitril/valsartan plus amlodipine was far superior to amlodipine alone in BP reduction. Ambulatory blood pressure monitoring (ABPM) demonstrated an SBP reduction of 13.9 mmHg in the sacubitril/valsartan plus amlodipine group, compared with 0.8 mmHg in the amlodipine monotherapy group (p<0.001). Adverse event rates were similar between groups (20.0 versus 21.3%, respectively) and included nasopharyngitis, dizziness, and upper respiratory tract infection as those most commonly reported. 17 Earlier studies of sacubitril/valsartan for the treatment of HTN compared various fixed-dose combinations against one another and against valsartan monotherapy. [18] [19] [20] [21] In each case, the higher the dose of sacubitril/valsartan, the more pronounced the BP-lowering effect. Studies of sacubitril/ valsartan 400 mg orally once daily yielded SBP reductions between 12.5 and 23.1 mmHg. [18] [19] [20] [21] Additionally, the combination of sacubitril/valsartan demonstrated superior BP lowering compared to valsartan monotherapy. 21 Adverse events were generally mild and of similar frequencies between groups with nasopharyngitis being the most commonly observed. [18] [19] [20] In contrast to the use of sacubitril/valsartan in patients with HF (either HFpEF or HFrEF), hypotension was rarely reported in patients treated with sacubitril/valsartan for HTN. Hypotension was either reported at an incidence of 1 to 2% or not reported at all. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] This is likely because the patients in the sacubitril/ valsartan HF studies typically had lower baseline BP values than those enrolled in the sacubitril/valsartan HTN studies and the treatment doses for HF were twice daily as opposed to once daily for HTN.
Ongoing studies of sacubitril/ valsartan in patients with hypertension
This article has reviewed the sacubitril/valsartan studies that have been completed in patients with HF with and without HTN and with HTN alone. There remain many questions on the optimal role sacubitril/valsartan can play in the management of patients with chronic HTN and/or resistant HTN. There are several completed studies with results on clinicaltrials.gov, but the final results are yet to be published in peer-reviewed journals. These completed, unpublished study findings are outlined in Table 2 . [22] [23] [24] These studies range from comparison trials with other ARBs, long-term tolerability studies, and studies evaluating sacubitril/valsartan as add-on therapy to amlodipine.
There are two clinical trials that have evaluated sacubitril/ valsartan compared with olmesartan in the treatment of HTN that have been completed but yet to have the final results published in the medical literature. 22, 23 These trials were 8 weeks in duration, similar to other published studies. These trials demonstrated a mean change in sitting SBP with sacubitril/valsartan in the range of -18 to -20 mmHg, but only one concluded sacubitril/valsartan to be noninferior to olmesartan, as the other reported no statistical analysis. 22, 23 ISSN: 1740-4398 REVIEW -Sacubitril/valsartan for the treatment of hypertension drugsincontext.com valsartan, and 13 of these were deemed serious. And there were no deaths. The types of adverse events are consistent with previously published trials. Unfortunately, no statistical analysis was performed on the outcome of adverse events in this trial. Secondary outcomes demonstrated similar mean changes in sitting SBP as previous studies have (in the -20 mmHg range).
As highlighted earlier, there are a number of studies evaluating sacubitril/valsartan for HTN, which are completed but not available in full form in the medical literature. There is a need to continue to push for these studies to be published in the medical literature to further describe the role of sacubitril/ valsartan in the management of hypertension. In addition, there is a greater need to further evaluate sacubitril/valsartan compared with all four of the first-line antihypertensive medication classes in a large trial in order to best determine the role of sacubitril/valsartan in HTN management across the general hypertensive population and in subpopulations. It is our hope these studies will be published in their full form in the future, but with many of them completing in 2015 to 2016, we may not see these published in full form moving forward.
Long-term safety and tolerability out to one year has been evaluated in one study that has been completed and is yet to be published in full form. 24 This study evaluated the ongoing safety of sacubitril/valsartan at doses of 200 mg orally once daily and 400 mg orally once daily as monotherapy and in combination with amlodipine and hydrochlorothiazide. The primary outcome was to evaluate the total number of adverse events, serious adverse events, and deaths in each of these treatment groups. The study included 341 patients across 4 treatment groups with 67% of patients receiving monotherapy with sacubitril/valsartan and only 4 patients receiving sacubitril/valsartan in combination with both amlodipine and hydrochlorothiazide. There were 231 total adverse events reported in patients receiving monotherapy with sacubitril/ ISSN: 1740-4398 
Conclusion
Sacubitril/valsartan is FDA and EMA approved for the treatment of HFpEF and has demonstrated safety and efficacy as an antihypertensive agent. Completed but not yet published studies of sacubitril/valsartan need to be fully described in the literature to aid in this determination. Given the available data, sacubitril/valsartan likely has a role as an antihypertensive agent, pending an expanded indication to include hypertension. If approved, it will be important to further study this agent against currently used antihypertensive agents to determine its specific role in therapy.
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